Shots:

• The collaboration is for development and commercialization of novel NK cell engager-based immunotherapeutics to treat multiple cancers
•  Affimed’s will use its ROCK platform (Redirected Optimized Cell Killing) to develop NK cell and T cell-engaging Abs and Genentech will take care of all global clinical development and commercialization
•  Affimed to receive an upfront $96M and additional payment of up to $5.0B including specified development- regulatory and commercial milestones with royalties on sales- with expected closure in Q3’18

         Ref: Affimed | Image:  Sec filling